 Home > Biochemistry News > Biotechnology News > Join forces to develop base editing therapy to treat complement-mediated diseases

Join forces to develop base editing therapy to treat complement-mediated diseases

 Last Update: 2021-08-07
 Source: Internet
 Author: User

Tags

list all diseases

kinetic research group

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On June 30, 2021, Apellis Pharmaceuticals and Beam Therapeutics jointly announced that the two companies have reached a five-year exclusive research collaboration and licensing agreement

Beam's base editing platform combines the characteristics of the CRISPR system to target specific DNA sequences with a base editing enzyme that chemically modifies DNA bases, enabling precise editing of individual bases

▲Principle of Beam's gene editing technology platform (picture source: Beam's official website)

Apellis has extensive experience in the development of complement therapy.

According to the agreement, Beam will be responsible for pre-clinical research on six projects, and Apellis will have the exclusive license rights for all projects and will assume the responsibility for subsequent development

Note: The original text has been deleted

Reference materials:

[1] Apellis and Beam Therapeutics Enter Exclusive Research Collaboration to Apply Base Editing to Discover Novel Therapies for Complement-Driven Diseases.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.